{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":898,"total_is_capped":false,"direct_labels_cover":3,"predictions_cover":898,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"072571263395","filters":{"topic":"Advanced Breast Cancer Therapies"}},"results":[{"id":"W2552099557","doi":"10.1056/nejmoa1607303","title":"Palbociclib and Letrozole in Advanced Breast Cancer","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2948,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Letrozole; Medicine; Breast cancer; Oncology; Estrogen receptor; Internal medicine; Cancer; Gynecology; Metastatic breast cancer; Tamoxifen","retraction":null,"screen_n_in":null,"score":{"opus":0.01120009148616708,"gpt":0.2938672739258823,"spread":0.2826671824397152,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003583706,0.0001431355,0.0005025183,0.0002087968,0.00001820963,0.000002566143,0.00007182988,0.00004555265,0.0005131245],"category_scores_gemma":[0.0001393885,0.00007171198,0.00003589525,0.0001596896,0.0001546279,0.0001827058,0.00001550724,0.0001857824,0.000001451569],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001207628,"about_ca_system_score_gemma":0.0001608677,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007498018,"about_ca_topic_score_gemma":0.00009600978,"domain_scores_codex":[0.9988539,0.00003828682,0.0004294379,0.0001336346,0.0003243392,0.0002203741],"domain_scores_gemma":[0.9990506,0.0001430166,0.0002325304,0.0001237609,0.0001455249,0.000304625],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.00298271,0.00002697605,0.1184023,0.00002540226,0.00005012645,0.0001678286,0.0004555015,0.000005555706,0.04259667,0.00005585585,0.0004358774,0.8347952],"study_design_scores_gemma":[0.2687008,0.001807069,0.5525709,0.006024655,0.0001737419,0.01092797,0.0004457327,0.00001073117,0.001911192,0.002582946,0.1545984,0.0002458284],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9119394,0.009777937,0.0008421389,0.07656315,0.0004319007,0.0001132881,0.000005248427,0.00001217082,0.0003147014],"genre_scores_gemma":[0.9916431,0.00308449,0.0005835693,0.0008941771,0.002972831,0.00000228625,4.089476e-7,0.00002095335,0.0007982114],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8345494,"threshold_uncertainty_score":0.5618353,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2290950904","doi":"10.1016/s1470-2045(15)00613-0","title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1822,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre; University of Calgary","funders":"University of California, Los Angeles; Novartis; Daiichi-Sankyo; Pfizer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline; U.S. Department of Defense","keywords":"Fulvestrant; Palbociclib; Metastatic breast cancer; Medicine; Placebo; Internal medicine; Oncology; Gynecology; Cancer; Breast cancer; Estrogen receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.1235990477317247,"gpt":0.4149209742192354,"spread":0.2913219264875107,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005927148,0.0005879899,0.00359845,0.0002012627,0.0001604418,0.00001360908,0.0004184213,0.0001275011,0.0002093901],"category_scores_gemma":[0.0001207619,0.0002531136,0.001133346,0.0005139093,0.0008510839,0.00009407445,0.00003016873,0.0001654767,0.000002385966],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001032316,"about_ca_system_score_gemma":0.0009422986,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003933841,"about_ca_topic_score_gemma":0.0005001402,"domain_scores_codex":[0.9962571,0.0008829798,0.001001024,0.0005819036,0.0005457136,0.0007312445],"domain_scores_gemma":[0.9924019,0.004889149,0.001384442,0.0008009481,0.0003689285,0.0001546299],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9266046,0.002847274,0.0000849642,0.00004482828,0.01823892,0.00001935493,0.00239656,0.0005480421,0.009399512,0.0001114962,0.00003489606,0.03966961],"study_design_scores_gemma":[0.9468176,0.01456339,0.00107265,0.0001402238,0.008859046,0.00002253284,0.0004638585,0.0006455318,0.02638,0.00003687253,0.0007420401,0.0002562884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9648197,0.002174971,0.0005811652,0.007998017,0.0006042545,0.02210978,0.001549025,0.0000544999,0.0001086103],"genre_scores_gemma":[0.9884078,0.002632072,0.0005891541,0.000171765,0.0005243631,0.007307405,0.00006232344,0.00005784004,0.0002472751],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03941332,"threshold_uncertainty_score":0.9999921,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2057272791","doi":"10.1038/nrd4504","title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","year":2015,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1762,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; Consortium canadien en neurodégénérescence associée au vieillissement; Cancer Research UK; F. Hoffmann-La Roche; Bristol-Myers Squibb","keywords":"Kinase; Cyclin; Cancer research; Targeted therapy; Cancer; Cyclin-dependent kinase; Cancer therapy; Medicine; Oncology; Biology; Internal medicine; Cell biology; Cell cycle","retraction":null,"screen_n_in":null,"score":{"opus":0.04203717735178965,"gpt":0.3749503544363558,"spread":0.3329131770845662,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001453065,0.0007051835,0.003629227,0.0001796534,0.00005727589,0.00002403956,0.0003789256,0.0005657483,0.00003740306],"category_scores_gemma":[0.0001485005,0.000364939,0.0006378672,0.0003415396,0.0002397734,0.0002420596,0.0001103486,0.002159873,0.000004475456],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001370296,"about_ca_system_score_gemma":0.001256746,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005930131,"about_ca_topic_score_gemma":0.0000940298,"domain_scores_codex":[0.9966142,0.0005270289,0.001276178,0.0006388936,0.0005426293,0.0004010705],"domain_scores_gemma":[0.9973902,0.0002982797,0.00127904,0.0007687554,0.0001386748,0.0001250413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009292194,0.00006569819,0.00003113935,0.0152862,0.0001432345,0.00001616744,0.0001783307,2.207315e-7,0.000002502811,0.0001035204,0.006923729,0.9771563],"study_design_scores_gemma":[0.0006088912,0.00003385307,0.00001624156,0.02576526,0.0004064743,0.00004201058,0.00009752568,1.829401e-7,0.000002307272,0.00005654718,0.9726442,0.0003265424],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000222447,0.9945078,0.000001143844,0.0003870101,0.002196859,0.00249143,0.00006908089,0.00002148072,0.0003029697],"genre_scores_gemma":[0.000006733282,0.9947885,0.00009716828,0.0003699991,0.001996497,0.0005244651,0.00007246072,0.0001069475,0.00203729],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9768298,"threshold_uncertainty_score":0.9998803,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1464936406","doi":"10.1056/nejmoa1505270","title":"Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1586,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Palbociclib; Medicine; Internal medicine; Oncology; Breast cancer; Hazard ratio; Exemestane; Clinical endpoint; Neutropenia; Placebo; Cancer; Metastatic breast cancer; Clinical trial; Estrogen receptor; Confidence interval; Chemotherapy; Tamoxifen; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.01997212785007568,"gpt":0.3116514899941887,"spread":0.2916793621441131,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006718406,0.0002221766,0.0007513828,0.0002809794,0.00002198484,0.000005258351,0.0001399448,0.00007775173,0.0002453896],"category_scores_gemma":[0.0002293086,0.0001471731,0.00007247949,0.0003773763,0.0001554161,0.0002570841,0.00002128544,0.0005516235,0.000008279507],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003967412,"about_ca_system_score_gemma":0.000586676,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002525043,"about_ca_topic_score_gemma":0.0000857758,"domain_scores_codex":[0.9981056,0.00008243375,0.000636236,0.0001752259,0.0006857328,0.0003147852],"domain_scores_gemma":[0.9981199,0.0001234094,0.0003827993,0.0001706558,0.0005168239,0.0006864169],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02043011,0.0001678926,0.03146693,0.00003085425,0.000226824,0.0005947942,0.006825725,0.0004662494,0.0290508,0.00009651361,0.007599422,0.9030439],"study_design_scores_gemma":[0.5085294,0.007221652,0.2690759,0.004791268,0.0004737162,0.01361141,0.005115315,0.00009457081,0.002899965,0.003184611,0.1843924,0.0006098035],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9192972,0.02486624,0.0009521561,0.0517895,0.001403407,0.000290615,0.00001889004,0.00002829329,0.001353752],"genre_scores_gemma":[0.9890461,0.001254961,0.001508573,0.001467999,0.006108653,0.000004808534,0.000007000406,0.00003807289,0.0005638381],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9024341,"threshold_uncertainty_score":0.6001545,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4206666777","doi":"10.1016/j.annonc.2020.09.010","title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1356,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"European Society for Medical Oncology; Novo Nordisk Fonden; European School of Oncology","keywords":"Medicine; Guideline; Multidisciplinary approach; Breast cancer; Expert opinion; Clinical Practice; Medical physics; Intensive care medicine; Cancer; Family medicine; Internal medicine; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.2443267065097386,"gpt":0.5038172245427751,"spread":0.2594905180330365,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001272885,0.0001535131,0.0004940691,0.00006230113,0.00003356233,0.000003069066,0.0001540189,0.0001040403,0.0005111333],"category_scores_gemma":[0.0004290606,0.0001367693,0.0001434072,0.0001184377,0.0001839763,0.00005586399,0.00004856503,0.0001155683,0.00001273309],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005726865,"about_ca_system_score_gemma":0.0003905557,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005459883,"about_ca_topic_score_gemma":0.00002896617,"domain_scores_codex":[0.9987882,0.00002408056,0.0004688517,0.0002837047,0.0001763647,0.0002587467],"domain_scores_gemma":[0.997509,0.0001552443,0.0002695917,0.0001480976,0.001756578,0.0001614998],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01063185,0.0002442334,0.003230452,0.0001539783,0.0006431012,0.00004201241,0.0004500065,0.0009326678,0.03137314,0.001072938,0.08146328,0.8697624],"study_design_scores_gemma":[0.006232047,0.001591584,0.0052161,0.0001142931,0.00007166845,0.0001734609,0.0004510733,0.0008656374,0.01278221,0.0008456929,0.9714748,0.0001814951],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.08913273,0.002207005,0.002326842,0.8997859,0.0009911924,0.0007565736,0.0007522416,0.0001121267,0.003935363],"genre_scores_gemma":[0.8713511,0.001144862,0.03287262,0.09117873,0.002232687,0.0002373245,0.00008000353,0.00006883746,0.0008338079],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.8900114,"threshold_uncertainty_score":0.5596551,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4239051461","doi":"10.1093/annonc/mdy192","title":"4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1190,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Oncology; Consensus conference; Medical physics; Cancer; Family medicine; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1732144412306442,"gpt":0.5044417495037564,"spread":0.3312273082731122,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002199605,0.0001551191,0.0004447701,0.000114963,0.0000537767,0.000003237762,0.0001565713,0.0001204078,0.0005638584],"category_scores_gemma":[0.0003341351,0.0001343153,0.0001228823,0.0001109935,0.0004581858,0.0000604044,0.00004703774,0.00008927345,0.00001560972],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008342386,"about_ca_system_score_gemma":0.0004101378,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001228714,"about_ca_topic_score_gemma":0.0001589154,"domain_scores_codex":[0.9987555,0.00002467428,0.0004632888,0.0002775294,0.0001762962,0.000302688],"domain_scores_gemma":[0.9957973,0.0001627991,0.0002880864,0.0002298578,0.00341667,0.0001052963],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007613084,0.0002791469,0.002744179,0.00005978198,0.0004947442,0.00001514375,0.0002378795,0.00007795763,0.02090154,0.001161158,0.06715311,0.8992622],"study_design_scores_gemma":[0.00519584,0.002020454,0.008253811,0.0001589759,0.00006097885,0.0003013167,0.0002785916,0.0003031187,0.02032196,0.002241369,0.9606933,0.0001702895],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.4282905,0.003683105,0.004388467,0.5386152,0.004850384,0.00146049,0.00113347,0.0001959496,0.01738239],"genre_scores_gemma":[0.9264634,0.0007045543,0.03758536,0.02789001,0.003554793,0.0002300996,0.00005304918,0.00006365794,0.00345503],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.899092,"threshold_uncertainty_score":0.6173854,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2804105316","doi":"10.1016/s1470-2045(18)30292-4","title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1011,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa","funders":"Astex Pharmaceuticals; Novartis","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Hormone receptor; Endocrine system; Hormone therapy; Gynecology; Cancer; Hormone","retraction":null,"screen_n_in":null,"score":{"opus":0.03244725651231038,"gpt":0.3715379082167767,"spread":0.3390906517044663,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006434701,0.0004429968,0.001435083,0.00008500854,0.0002995978,0.00002369784,0.0003842022,0.0001242978,0.0007307226],"category_scores_gemma":[0.00005829521,0.0002654959,0.0001093983,0.0002980472,0.000845491,0.0001793721,0.00005855953,0.0003673904,0.0000251718],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001101276,"about_ca_system_score_gemma":0.0008761207,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005566329,"about_ca_topic_score_gemma":0.00006673896,"domain_scores_codex":[0.9971992,0.0002597807,0.0004852153,0.0005944814,0.000351376,0.001109918],"domain_scores_gemma":[0.9977175,0.0005559595,0.000395161,0.0006271054,0.0004687953,0.0002354821],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7863739,0.0005952446,0.00003480255,0.00002703694,0.000775877,0.00001708837,0.001609225,0.00001822545,0.06990329,0.0001286896,0.001461492,0.1390552],"study_design_scores_gemma":[0.751824,0.02633149,0.001157779,0.0000683643,0.0001533673,0.0002564259,0.0003196104,0.00009108242,0.00536067,0.0002548399,0.2138532,0.0003291532],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9734614,0.001519633,0.001947276,0.01364763,0.0006891019,0.006877567,0.0005947945,0.0002318749,0.001030644],"genre_scores_gemma":[0.9709054,0.0009339511,0.004088308,0.005397411,0.008384014,0.008894483,0.00008738841,0.0001381065,0.001170922],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2123917,"threshold_uncertainty_score":0.9999797,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3133509869","doi":"10.1056/nejmoa1911149","title":"Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":841,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis","keywords":"Fulvestrant; Oncology; Medicine; Internal medicine; Interim analysis; Cancer; Breast cancer; Human Epidermal Growth Factor Receptor 2; Hormone receptor; Metastatic breast cancer; Clinical trial; Estrogen receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.01125536094792389,"gpt":0.2819309661319838,"spread":0.2706756051840599,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004543486,0.0002394642,0.0009082089,0.0002295462,0.00001855193,0.000005590348,0.0001414877,0.00006429252,0.0009287264],"category_scores_gemma":[0.00003901189,0.0001407357,0.00006365944,0.0002598855,0.0001098417,0.0002385224,0.00001374786,0.0005963921,0.000005831987],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002889163,"about_ca_system_score_gemma":0.0006336733,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003726733,"about_ca_topic_score_gemma":0.0002646866,"domain_scores_codex":[0.9981186,0.00005779476,0.0005600994,0.0002048995,0.00071865,0.0003399672],"domain_scores_gemma":[0.9986746,0.0001387973,0.000368529,0.0002254396,0.0002431978,0.0003494432],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.05752128,0.0002046937,0.3611965,0.0003006533,0.0005125848,0.001574342,0.003811431,0.00626635,0.03679983,0.0003476434,0.0003744848,0.5310903],"study_design_scores_gemma":[0.3509834,0.00427553,0.5875906,0.005324875,0.0002584689,0.01023474,0.001062097,0.0001215096,0.0005122765,0.0006100159,0.03867001,0.0003565555],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9773268,0.003250249,0.0004762051,0.01682337,0.0008516035,0.0002809729,0.000007364144,0.0000174142,0.0009660087],"genre_scores_gemma":[0.9937384,0.000640539,0.0009623072,0.0008585639,0.002757485,0.000002808566,0.000003863818,0.00004065941,0.0009953774],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5307337,"threshold_uncertainty_score":0.9999846,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2558360748","doi":"10.1016/s0140-6736(16)32389-3","title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":602,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital","funders":"AstraZeneca","keywords":"Anastrozole; Fulvestrant; Medicine; Internal medicine; Hazard ratio; Breast cancer; Oncology; Clinical endpoint; Population; Placebo; Aromatase inhibitor; Metastatic breast cancer; Cancer; Gynecology; Randomized controlled trial; Estrogen receptor; Tamoxifen; Confidence interval; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.06965433626529506,"gpt":0.3886010275041646,"spread":0.3189466912388696,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004040473,0.0003379757,0.0007709395,0.00008745256,0.0001611541,0.00004206971,0.0004919766,0.0001006819,0.0004099207],"category_scores_gemma":[0.00006137117,0.0001970381,0.0002128106,0.000155613,0.0002603994,0.0005401084,0.00004629786,0.0002077077,0.00002682193],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003276011,"about_ca_system_score_gemma":0.0001888759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000725434,"about_ca_topic_score_gemma":0.00004998942,"domain_scores_codex":[0.997995,0.00007944641,0.0004365354,0.0005049037,0.0003893116,0.0005947708],"domain_scores_gemma":[0.9981545,0.0003221635,0.0002855678,0.0007148891,0.0003116397,0.0002112695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8069151,0.0002674431,0.00003374582,0.00001257086,0.0004969152,0.00000465542,0.0002382856,0.00001958472,0.07362571,0.0003398029,0.0008609623,0.1171852],"study_design_scores_gemma":[0.9508999,0.001876206,0.0005531575,0.0001904401,0.0002289251,0.00003572273,0.0002138267,0.00005480605,0.01070174,0.0001429965,0.03480392,0.0002983827],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9596859,0.0008024973,0.004818618,0.02436425,0.002495095,0.004128071,0.002723836,0.0002158706,0.0007658394],"genre_scores_gemma":[0.9843453,0.001035237,0.002020671,0.0008446562,0.008925488,0.001793424,0.0002430243,0.00009358166,0.0006986],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1439848,"threshold_uncertainty_score":0.8034981,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2151082560","doi":"10.1093/annonc/mdu456","title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":568,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital du Saint-Sacrement; Sunnybrook Health Science Centre; University of Toronto","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Exemestane; Human Epidermal Growth Factor Receptor 2; Everolimus; Oncology; Internal medicine; Hormone receptor; Breast cancer; Cancer research; Cancer; Aromatase","retraction":null,"screen_n_in":null,"score":{"opus":0.0499435101726918,"gpt":0.3632289122475997,"spread":0.313285402074908,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004370143,0.0005397518,0.001643782,0.000176005,0.0001935874,0.00001346755,0.0003425198,0.0003844004,0.000322298],"category_scores_gemma":[0.0005505847,0.0005082938,0.0003498594,0.0002099389,0.0004801385,0.0003804804,0.0001130224,0.0004209298,0.00002368018],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004670301,"about_ca_system_score_gemma":0.0004472021,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002070168,"about_ca_topic_score_gemma":0.0003155833,"domain_scores_codex":[0.9963523,0.000340002,0.001054734,0.0009007655,0.0004618563,0.0008902976],"domain_scores_gemma":[0.9952018,0.001589344,0.0009393453,0.0005474329,0.001334639,0.0003874701],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1136911,0.001390581,0.002692879,0.0002318329,0.002218731,0.00003147854,0.00527135,0.0003700042,0.3965859,0.002771002,0.01446049,0.4602846],"study_design_scores_gemma":[0.09179001,0.02004953,0.5504739,0.0008658407,0.0004381523,0.00007336158,0.001137575,0.0003817494,0.1871324,0.008502736,0.1371137,0.00204099],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9635448,0.001010378,0.001841237,0.01806454,0.00110147,0.001663294,0.009624958,0.000184961,0.002964386],"genre_scores_gemma":[0.9879792,0.0007705692,0.005833525,0.002502189,0.001226636,0.0002392852,0.0007613286,0.0001153114,0.0005719418],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5477811,"threshold_uncertainty_score":0.9997368,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2908699784","doi":"10.1007/s10549-018-05125-4","title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","year":2019,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":442,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; University of Alberta","funders":"Pfizer","keywords":"Palbociclib; Letrozole; Medicine; Breast cancer; Oncology; Internal medicine; Placebo; Metastatic breast cancer; Hazard ratio; Estrogen receptor; Population; Cancer; Gynecology; Tamoxifen; Confidence interval; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.03527075155297768,"gpt":0.3551255762284284,"spread":0.3198548246754507,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002174952,0.0007823654,0.001138012,0.0004373759,0.000403417,0.00008786599,0.0002521074,0.0001901301,0.003729091],"category_scores_gemma":[0.00001754942,0.0005576864,0.0001813058,0.0008662533,0.0005710067,0.0005514957,0.0001106678,0.0006400673,0.000103425],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003728239,"about_ca_system_score_gemma":0.001206885,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01750112,"about_ca_topic_score_gemma":0.003204925,"domain_scores_codex":[0.9952238,0.000254408,0.0005185457,0.001367177,0.001116753,0.001519341],"domain_scores_gemma":[0.9973221,0.0002773862,0.0002136756,0.0006325006,0.0008238278,0.000730493],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.09151347,0.002199138,0.3704019,0.0002433163,0.002396397,0.0002487898,0.004044095,0.0001154091,0.0238848,0.0005213197,0.0001098071,0.5043216],"study_design_scores_gemma":[0.08115394,0.01076672,0.8512605,0.001912315,0.0001017267,0.000565167,0.001858929,0.00005255242,0.04795021,0.0005147713,0.002721851,0.001141315],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814484,0.0040643,0.0000119581,0.008308101,0.0001797214,0.00351664,0.001971886,0.0001140568,0.0003849991],"genre_scores_gemma":[0.9854721,0.007076696,0.0003183621,0.0002381077,0.0004247411,0.002688947,0.0001692717,0.0001693882,0.003442337],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5031803,"threshold_uncertainty_score":0.9996874,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3024684302","doi":"10.1158/2159-8290.cd-19-1390","title":"The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":433,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Alberta Cancer Foundation; Jewish General Hospital; Institute of Cancer Research","funders":"National Cancer Institute; Susan G. Komen; American Association for Cancer Research; U.S. Department of Defense","keywords":"Cancer research; Breast cancer; KRAS; AKT1; Cancer; Metastatic breast cancer; Cyclin-dependent kinase 4; CHEK1; Kinase; Biology; Estrogen receptor; Cyclin-dependent kinase 6; Medicine; Internal medicine; Cell cycle; Cyclin-dependent kinase; Cell cycle checkpoint; Signal transduction; PI3K/AKT/mTOR pathway; Cyclin-dependent kinase 2; Genetics; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.007344171976413173,"gpt":0.2373030143662544,"spread":0.2299588423898413,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008748005,0.000257125,0.0004799792,0.00007493191,0.00007662762,0.00003636763,0.000132461,0.00003769357,0.00002377427],"category_scores_gemma":[0.00002726606,0.0001741142,0.00004850549,0.0004282435,0.0001928748,0.0002920528,0.00009580595,0.0001483926,0.000002744822],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003723295,"about_ca_system_score_gemma":0.0002796442,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002105172,"about_ca_topic_score_gemma":0.0006537883,"domain_scores_codex":[0.9984089,0.00005672083,0.0003773775,0.0004550187,0.0003660433,0.0003359914],"domain_scores_gemma":[0.9990959,0.0000839889,0.0002099365,0.0002580452,0.0001495941,0.0002025877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06960879,0.0004097669,0.756654,0.0005088196,0.0009771134,0.00004664923,0.006766419,0.0009471795,0.03515172,0.0001375072,0.001320492,0.1274716],"study_design_scores_gemma":[0.006588249,0.0004376443,0.9853914,0.0006679444,0.0001558163,0.000002297294,0.0009065524,0.000007460707,0.004499393,0.00003161699,0.001021821,0.0002897387],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9796846,0.01323265,0.00008085025,0.005135528,0.0001349518,0.0009350092,0.0007347307,0.00001979101,0.00004191355],"genre_scores_gemma":[0.9970879,0.001155835,0.0001712114,0.0009760549,0.0001805788,0.0002195237,0.00002200713,0.00005121604,0.0001356793],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2287375,"threshold_uncertainty_score":0.7100171,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4386102828","doi":"10.1016/s0140-6736(23)01245-x","title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":427,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"MacroGenics; Puma Biotechnology; Mylan; Gilead Sciences; Amgen; Pfizer; Samsung; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Oncology; Clinical endpoint; Breast cancer; Hazard ratio; Taxane; Cancer; Clinical trial; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.05675231104043848,"gpt":0.3583262430471858,"spread":0.3015739320067473,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005403872,0.0004663427,0.001526893,0.0001530807,0.0002459273,0.0001114667,0.0003994302,0.00007708608,0.0003158367],"category_scores_gemma":[0.0001712503,0.0003028763,0.00006394285,0.0005973348,0.0004002387,0.0004224034,0.0001837859,0.0005516948,0.00002502863],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004470126,"about_ca_system_score_gemma":0.0002164359,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002874128,"about_ca_topic_score_gemma":0.0008920599,"domain_scores_codex":[0.997019,0.0005685259,0.0005303611,0.0006211954,0.0004811445,0.0007798059],"domain_scores_gemma":[0.9980416,0.0007137109,0.0003385429,0.0004923274,0.0001906724,0.0002231561],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9407873,0.001114284,0.002557785,0.0001746658,0.001422434,0.0001249174,0.005995466,0.00002853279,0.02479061,0.0009918552,0.001512204,0.02049999],"study_design_scores_gemma":[0.9504325,0.002154727,0.040953,0.0004428224,0.0003062632,0.00005199385,0.001059533,0.0001526663,0.002365462,0.0006660592,0.0008348606,0.0005800706],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860409,0.0004104,0.0001010053,0.006883221,0.0002302168,0.004239284,0.001683889,0.0001421952,0.000268841],"genre_scores_gemma":[0.9949746,0.0005851753,0.001064715,0.0007549887,0.001021443,0.0008135875,0.0001731912,0.00009894355,0.0005134036],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03839521,"threshold_uncertainty_score":0.9999424,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4392977246","doi":"10.1056/nejmoa2305488","title":"Ribociclib plus Endocrine Therapy in Early Breast Cancer","year":2024,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":357,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Letrozole; Breast cancer; Anastrozole; Internal medicine; Goserelin; Oncology; Aromatase inhibitor; Cancer; Interim analysis; Clinical endpoint; Tamoxifen; Gynecology; Randomized controlled trial","retraction":null,"screen_n_in":null,"score":{"opus":0.02150004405986991,"gpt":0.3288692249692114,"spread":0.3073691809093416,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004593209,0.0002072587,0.0006353599,0.0004190553,0.00002089633,0.000014143,0.0001303299,0.00005150373,0.001023418],"category_scores_gemma":[0.00005379739,0.0001245163,0.00009633062,0.0004530209,0.0001223598,0.0002105506,0.00001397359,0.0006702103,0.000007722351],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000281453,"about_ca_system_score_gemma":0.0005545359,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007190362,"about_ca_topic_score_gemma":0.00008353357,"domain_scores_codex":[0.9983377,0.00005474014,0.0005807334,0.0001802148,0.000549514,0.0002971189],"domain_scores_gemma":[0.9990512,0.0001696839,0.0001423911,0.0001609076,0.0001673326,0.0003085608],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004659812,0.00005021739,0.01902098,0.00008612498,0.0002732495,0.00247529,0.003553689,0.00008621799,0.009701113,0.0001857143,0.002066855,0.9578407],"study_design_scores_gemma":[0.1866103,0.003976997,0.2494176,0.007831814,0.000292389,0.03151877,0.0005243207,0.000235814,0.001708284,0.003476265,0.5140362,0.0003711733],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8568761,0.06951894,0.0006986659,0.06998052,0.001938068,0.0002335977,0.00001089128,0.00005235921,0.0006908451],"genre_scores_gemma":[0.9798521,0.006856561,0.0003075865,0.001140202,0.01056708,0.000004874812,0.000002330391,0.00004434096,0.001224955],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9574696,"threshold_uncertainty_score":0.9998898,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2947470150","doi":"10.1038/s41523-019-0111-0","title":"SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer","year":2019,"lang":"en","type":"article","venue":"npj Breast Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":355,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa","funders":"National Cancer Institute; National Institutes of Health; Berlin Institute of Health; Deutsche Forschungsgemeinschaft; Breast Cancer Research Foundation","keywords":"Breast cancer; Metastatic breast cancer; Medicine; Internal medicine; Oncology; Cancer; Targeted therapy; Endocrine system; Hormone; Bioinformatics; Cancer research; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.03199847053610999,"gpt":0.3266311783684151,"spread":0.2946327078323051,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003330502,0.0006902224,0.001178444,0.0002346644,0.000164559,0.00005585355,0.0002235414,0.0001170738,0.002315165],"category_scores_gemma":[0.00002973372,0.0005862804,0.000442621,0.0004129428,0.0001202258,0.0003472501,0.00007883855,0.0002594754,0.00004742214],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001054284,"about_ca_system_score_gemma":0.0008138126,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001060216,"about_ca_topic_score_gemma":0.0004112454,"domain_scores_codex":[0.9964226,0.0000752547,0.0005678834,0.001142463,0.0005840157,0.001207753],"domain_scores_gemma":[0.9971489,0.0002722469,0.000269538,0.0008337447,0.0009294971,0.0005461115],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0440372,0.00110273,0.0604785,0.001650555,0.003312977,0.00005403517,0.0009740553,0.008526247,0.2300238,0.0001708094,0.00830463,0.6413645],"study_design_scores_gemma":[0.06798769,0.002602294,0.6036634,0.002382181,0.00177402,0.005358204,0.0005842158,0.01002692,0.05992063,0.0006537287,0.241713,0.003333699],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8555619,0.004757583,0.04162699,0.03539854,0.003445121,0.01542367,0.04290551,0.0006684224,0.0002122586],"genre_scores_gemma":[0.9636698,0.0004170219,0.01403286,0.008036634,0.002854286,0.007095453,0.0002597266,0.0003655188,0.003268699],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6380308,"threshold_uncertainty_score":0.9996589,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3141372695","doi":"10.1016/s1470-2045(21)00034-6","title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Aromatase inhibitor; Internal medicine; Oncology; Breast cancer; Cancer; Cohort; Regimen; Clinical endpoint; Clinical trial; Estrogen receptor; Aromatase","retraction":null,"screen_n_in":null,"score":{"opus":0.05096464552649327,"gpt":0.3993410276253444,"spread":0.3483763820988511,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062193,0.0004756447,0.002331764,0.0001322141,0.0000993648,0.00002923351,0.0004830911,0.0001798179,0.0004314722],"category_scores_gemma":[0.00005702757,0.0003730007,0.00008176919,0.0008648651,0.0004567685,0.0003278388,0.0003616268,0.000810465,0.00003132568],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001222526,"about_ca_system_score_gemma":0.001223746,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008282925,"about_ca_topic_score_gemma":0.002697835,"domain_scores_codex":[0.996336,0.000641296,0.0009027992,0.0008396989,0.0004663384,0.0008138306],"domain_scores_gemma":[0.9974946,0.0003674177,0.0004751424,0.0008178459,0.0006364345,0.0002085006],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.3030126,0.04400807,0.02938606,0.000280704,0.004362649,0.002779641,0.06302731,0.001009377,0.4672002,0.00008402509,0.000948243,0.0839011],"study_design_scores_gemma":[0.3867896,0.01146732,0.5113239,0.001880643,0.001396089,0.0007895908,0.03543576,0.001503092,0.04345934,0.0001406372,0.004492774,0.001321241],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985802,0.003166675,0.0001660683,0.004376505,0.0003509767,0.004251107,0.0006441794,0.00005038966,0.00119213],"genre_scores_gemma":[0.991376,0.0007411645,0.003922397,0.001317318,0.0005170534,0.001685018,0.00009132913,0.00006405955,0.000285652],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4819379,"threshold_uncertainty_score":0.9998722,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3148345241","doi":"10.1200/jco.20.03639","title":"Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":324,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Palbociclib; Oncology; Internal medicine; Lapatinib; Taxane; Breast cancer; Letrozole; Estrogen receptor; Hormone receptor; Aromatase inhibitor; Gynecology; Tamoxifen; Cancer; Trastuzumab; Metastatic breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.08584686499972378,"gpt":0.4566029099254679,"spread":0.3707560449257442,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00223858,0.0002038958,0.001622408,0.00005865182,0.0001544877,0.000024411,0.0001706058,0.0003489904,0.0001752961],"category_scores_gemma":[0.006753688,0.0001293291,0.000424999,0.0001609852,0.000638083,0.000158922,0.00009182459,0.001237898,0.000004038528],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002307514,"about_ca_system_score_gemma":0.004112468,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000387713,"about_ca_topic_score_gemma":0.001135228,"domain_scores_codex":[0.9962011,0.001011183,0.00177685,0.0003225135,0.0003736487,0.0003147351],"domain_scores_gemma":[0.9828402,0.0127425,0.002197641,0.0002122551,0.001658152,0.0003492074],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.3961377,0.001294391,0.03206012,0.00005085299,0.002996776,0.0008638207,0.001902809,0.0000314346,0.0002929161,0.0004960574,0.002871875,0.5610013],"study_design_scores_gemma":[0.1734399,0.01989647,0.7739491,0.0003400675,0.001539352,0.001432862,0.001384064,0.00000641762,0.001353788,0.01054469,0.01590051,0.0002128026],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9484771,0.001130731,0.0002923344,0.04723077,0.001822373,0.0006586547,0.0001598968,0.000009022399,0.0002191134],"genre_scores_gemma":[0.9764476,0.0033048,0.007187895,0.005067399,0.007217272,0.00005826026,0.000004953425,0.00004160667,0.0006701474],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.741889,"threshold_uncertainty_score":0.8085283,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3167855488","doi":"10.1016/j.annonc.2021.05.353","title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals","keywords":"Medicine; Fulvestrant; Internal medicine; Hazard ratio; Population; Breast cancer; Placebo; Metastatic breast cancer; Progression-free survival; Clinical endpoint; Oncology; Cancer; Randomized controlled trial; Gastroenterology; Confidence interval; Chemotherapy; Estrogen receptor; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.04265747474552653,"gpt":0.3792816454752698,"spread":0.3366241707297433,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001063412,0.0004857282,0.002456988,0.0001656542,0.0001513445,0.00001879772,0.0002606466,0.0002351528,0.0007674973],"category_scores_gemma":[0.0002773476,0.0003348687,0.000230853,0.000447331,0.0006769531,0.0003261646,0.0000541309,0.0004811682,0.00000290571],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004709397,"about_ca_system_score_gemma":0.001182042,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003499217,"about_ca_topic_score_gemma":0.0001972258,"domain_scores_codex":[0.9958178,0.001087515,0.001100195,0.0006680652,0.000474279,0.0008521482],"domain_scores_gemma":[0.9957386,0.001704709,0.0007825748,0.0003748723,0.001170896,0.000228369],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8846304,0.001843697,0.00003104082,0.00005985728,0.001359015,0.00009446558,0.004889777,0.00004962413,0.08075035,0.0007110148,0.0003530891,0.02522764],"study_design_scores_gemma":[0.951797,0.01434466,0.004518868,0.0001513401,0.0002141405,0.0001149614,0.002573275,0.00002920755,0.02138126,0.00115568,0.003257031,0.000462569],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9741296,0.001107716,0.000340599,0.01746216,0.0002847727,0.004189741,0.001942044,0.00005400893,0.0004893162],"genre_scores_gemma":[0.9915453,0.001140194,0.001462855,0.002622937,0.0003925349,0.001974408,0.0004822472,0.00008174973,0.000297735],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06716657,"threshold_uncertainty_score":0.9999104,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4200069316","doi":"10.1158/1078-0432.ccr-21-3032","title":"Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa","funders":"National Cancer Institute; Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation","keywords":"Overall survival; Randomized controlled trial; Endocrine system; Clinical trial; Breast cancer; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.127275101733424,"gpt":0.5170188085085538,"spread":0.3897437067751297,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004591967,0.0005935685,0.003676051,0.0003670712,0.0001067768,0.00004609111,0.0004113522,0.0002744882,0.001461527],"category_scores_gemma":[0.001145524,0.0004498555,0.0003635328,0.00120262,0.002015034,0.0003422457,0.0002796125,0.002305078,0.000002868921],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006053504,"about_ca_system_score_gemma":0.00287704,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00319495,"about_ca_topic_score_gemma":0.002516824,"domain_scores_codex":[0.988948,0.003527741,0.002920198,0.001571729,0.001756671,0.001275609],"domain_scores_gemma":[0.9914144,0.005003305,0.0005807471,0.0009530833,0.001462678,0.0005857337],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8002751,0.005246344,0.05308923,0.00005888161,0.0008418174,0.0002322805,0.000283044,0.0001017073,0.000923507,0.00005458034,0.00003236589,0.1388611],"study_design_scores_gemma":[0.858683,0.006350848,0.130488,0.0004156159,0.00007067424,0.00001179383,0.0001264623,0.0002528024,0.0008577271,0.0001024411,0.002246435,0.0003941558],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9795967,0.011445,0.00001893184,0.002413739,0.0009308771,0.005080567,0.0003406804,0.00005271441,0.0001207459],"genre_scores_gemma":[0.9586929,0.03761403,0.0003313125,0.0003170473,0.0008100839,0.001509141,0.0001765014,0.0001313783,0.0004175887],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.138467,"threshold_uncertainty_score":0.9999967,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3020482066","doi":"10.1016/s1470-2045(20)30112-1","title":"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":261,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Eisai; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Fulvestrant; Internal medicine; Breast cancer; Oncology; Metastatic breast cancer; Cancer; Chemotherapy; Tamoxifen","retraction":null,"screen_n_in":null,"score":{"opus":0.05342743091466359,"gpt":0.3829554564653619,"spread":0.3295280255506983,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005428988,0.0007474941,0.003510928,0.000114869,0.0001809517,0.00004691131,0.0006968445,0.0002405826,0.0004747813],"category_scores_gemma":[0.00005384568,0.0004461976,0.00008638174,0.0009333872,0.001033806,0.0003433683,0.0001165535,0.001009205,0.000006258132],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003914137,"about_ca_system_score_gemma":0.00413163,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002072303,"about_ca_topic_score_gemma":0.0006096729,"domain_scores_codex":[0.9957322,0.000600987,0.0008247943,0.0009859314,0.0007050584,0.001151022],"domain_scores_gemma":[0.9972798,0.0006044228,0.0006610068,0.0006129689,0.0004130065,0.0004288199],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8245567,0.0008862953,0.00003322951,0.0001702537,0.001142556,0.0002907111,0.03222229,0.0003566729,0.006510944,0.00002675874,0.00007793835,0.1337256],"study_design_scores_gemma":[0.8765252,0.09846667,0.0005172402,0.0006340889,0.0003476645,0.0002977377,0.01478693,0.0001879633,0.002551254,0.00001541097,0.005072714,0.0005970846],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9714132,0.002106033,0.001199873,0.01428448,0.0001908588,0.008647365,0.001182818,0.000142461,0.000832907],"genre_scores_gemma":[0.9861772,0.001556678,0.005922321,0.002477188,0.0008035535,0.002700649,0.00008627267,0.0001877813,0.00008836341],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1331286,"threshold_uncertainty_score":0.9999096,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3120241209","doi":"10.1016/s1470-2045(20)30642-2","title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"Pfizer","keywords":"Palbociclib; Interim analysis; Medicine; Interim; Adjuvant; Oncology; Breast cancer; Internal medicine; Cancer; Endocrine system; Adjuvant therapy; Gynecology; Clinical trial; Metastatic breast cancer; History; Hormone","retraction":null,"screen_n_in":null,"score":{"opus":0.08323415090640111,"gpt":0.4366332390939129,"spread":0.3533990881875118,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005144823,0.0002679033,0.002004261,0.0001886004,0.00005438863,0.00002257424,0.0004533727,0.00005856576,0.0007633908],"category_scores_gemma":[0.00004625019,0.0001610139,0.00008946756,0.001340694,0.000217359,0.0001145542,0.0001839986,0.0003667798,0.000004039081],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002780326,"about_ca_system_score_gemma":0.0004498715,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001993514,"about_ca_topic_score_gemma":0.009135486,"domain_scores_codex":[0.9976203,0.0005930369,0.0005600698,0.0004727787,0.0002703981,0.000483405],"domain_scores_gemma":[0.9980815,0.0003824829,0.0003427133,0.0007828522,0.0003087317,0.0001017164],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3642294,0.01466992,0.3432846,0.00006347106,0.01149025,0.001476373,0.01341592,0.0003526935,0.02206589,0.00006431926,0.00008166007,0.2288054],"study_design_scores_gemma":[0.6183466,0.00550858,0.3610713,0.000180173,0.002492138,0.0002421851,0.004477841,0.0007064948,0.002235468,0.00003700159,0.004391242,0.0003110356],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899983,0.0020011,0.00009647845,0.005373264,0.000112545,0.001824767,0.0001220507,0.00003277621,0.0004387046],"genre_scores_gemma":[0.995307,0.001142023,0.0007379276,0.001732468,0.0001895224,0.0005554744,0.00002740439,0.00003758196,0.0002705535],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2541171,"threshold_uncertainty_score":0.8358594,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2474699717","doi":"10.1634/theoncologist.2016-0097","title":"Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"National Cancer Institute; AstraZeneca; Pfizer","keywords":"Medicine; Palbociclib; Fulvestrant; Neutropenia; Placebo; Metastatic breast cancer; Internal medicine; Adverse effect; Febrile neutropenia; Oncology; Common Terminology Criteria for Adverse Events; Breast cancer; Cancer; Chemotherapy; Estrogen receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.009780463777112593,"gpt":0.2961600474988715,"spread":0.2863795837217589,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001637433,0.0005385301,0.002782019,0.000368302,0.0001399998,0.00003040523,0.0002783897,0.00007535746,0.0002983999],"category_scores_gemma":[0.0001984554,0.0002488737,0.0001624124,0.001277117,0.0009329398,0.0003297587,0.00005179965,0.0003778697,0.000007260314],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002084187,"about_ca_system_score_gemma":0.0003142217,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003258374,"about_ca_topic_score_gemma":0.01761851,"domain_scores_codex":[0.9954724,0.001562737,0.001007919,0.0007344231,0.0005777818,0.0006447301],"domain_scores_gemma":[0.995349,0.002872747,0.0007854419,0.0005480141,0.0002682832,0.0001764918],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.922018,0.00410069,0.01005934,0.00001070193,0.005557809,0.0001590918,0.008550045,0.0008919238,0.002119895,0.00001275703,0.000001942788,0.04651782],"study_design_scores_gemma":[0.8678102,0.00320548,0.1114971,0.0003666551,0.002477429,0.00001269116,0.01316927,0.0007200459,0.0002259359,0.0001513913,0.00001107496,0.0003526542],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9820181,0.0004904721,0.005325763,0.003071016,0.00004696229,0.008514379,0.0003606701,0.00007728184,0.00009541795],"genre_scores_gemma":[0.9925421,0.0004480006,0.001485648,0.0002197664,0.00004035548,0.004999788,0.00003646436,0.00005300854,0.0001748175],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1014378,"threshold_uncertainty_score":0.9999964,"prediction_status":"machine_predicted_unvalidated"},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2902672529","doi":"10.1200/jco.18.01624","title":"Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; Centre hospitalier de l'Université Laval; Institute of Cancer Research; Jewish General Hospital","funders":"Daiichi Sankyo Europe; Genentech; Astellas Pharma; Eisai; Cancer Research UK; GlaxoSmithKline; Public Health Agency; MacroGenics; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Genomic Health","keywords":"Letrozole; Palbociclib; Medicine; Breast cancer; Estrogen receptor; Internal medicine; Oncology; Urology; Cancer; Metastatic breast cancer; Tamoxifen","retraction":null,"screen_n_in":null,"score":{"opus":0.1484660686979292,"gpt":0.5541645440786152,"spread":0.405698475380686,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01003618,0.0002584928,0.003037972,0.0003465216,0.00007740027,0.00001374103,0.000230912,0.0002949055,0.001080416],"category_scores_gemma":[0.003650106,0.0001876685,0.0004905905,0.0004223569,0.0003316455,0.0002221095,0.00006935349,0.001178228,0.00002503176],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005966565,"about_ca_system_score_gemma":0.001951102,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003810175,"about_ca_topic_score_gemma":0.0002923522,"domain_scores_codex":[0.9920538,0.002878946,0.003578698,0.0003836477,0.0006869244,0.0004179516],"domain_scores_gemma":[0.9935607,0.003008453,0.002028533,0.0002291822,0.0007859872,0.0003871666],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5968614,0.005586331,0.003578897,0.000001782593,0.0003575138,0.0001409627,0.002015172,0.00001957424,0.0006915145,0.00000942425,0.00009838524,0.390639],"study_design_scores_gemma":[0.8181682,0.1622614,0.01589346,0.0002977987,0.0001688255,0.0001014708,0.0009026687,0.00006993795,0.0001381078,0.000369147,0.001477676,0.0001512527],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9862159,0.0004356013,0.0001002413,0.008637832,0.001692332,0.002711985,0.00002800372,0.00001315099,0.0001649414],"genre_scores_gemma":[0.9899292,0.0003796982,0.002097246,0.0025364,0.004753292,0.0002057974,0.000005529632,0.00003611048,0.00005670892],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3904877,"threshold_uncertainty_score":0.9998327,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2974027076","doi":"10.1158/1078-0432.ccr-19-0751","title":"Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer","year":2019,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Letrozole; Breast cancer; Biomarker; Cyclin-dependent kinase 4; Oncology; Metastatic breast cancer; Medicine; Internal medicine; Cancer; Fulvestrant; Cancer research; Biology; Estrogen receptor; Cell cycle; Tamoxifen; Cyclin-dependent kinase 2","retraction":null,"screen_n_in":null,"score":{"opus":0.264754332948068,"gpt":0.543597462485185,"spread":0.278843129537117,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00226576,0.000610098,0.002020563,0.001290552,0.0000849119,0.00004746317,0.0002534653,0.0003698666,0.001053109],"category_scores_gemma":[0.0003118988,0.0004168844,0.000193022,0.001268268,0.0009942503,0.0001467228,0.0001669645,0.002116588,0.00002460966],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002217516,"about_ca_system_score_gemma":0.002116702,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005869604,"about_ca_topic_score_gemma":0.0005682021,"domain_scores_codex":[0.9926385,0.00190299,0.0012497,0.001405506,0.001563361,0.001239942],"domain_scores_gemma":[0.9942145,0.003088383,0.000368925,0.001086247,0.0008685737,0.0003733123],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.3665779,0.001724221,0.03707979,0.001303355,0.004112544,0.004609002,0.001148203,0.0001014053,0.03593561,0.00000145941,0.02145264,0.5259539],"study_design_scores_gemma":[0.07245899,0.02696307,0.6071531,0.008105678,0.0007516331,0.0004984735,0.001426319,0.00005493655,0.01343852,0.0003090666,0.2669629,0.001877295],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7325886,0.004860964,0.00001054107,0.2590171,0.00015248,0.002331843,0.0009735498,0.00002789848,0.00003710277],"genre_scores_gemma":[0.8352911,0.01951531,0.0004680205,0.1299591,0.002131897,0.005852422,0.0001524962,0.0003902667,0.006239331],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5700733,"threshold_uncertainty_score":0.99986,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4396732203","doi":"10.1016/j.annonc.2024.04.013","title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Regional Municipality of Durham","funders":"Sanofi Genzyme; Gilead Sciences; Sanofi; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Nonsteroidal; Aromatase inhibitor; Aromatase; Oncology; Internal medicine; Breast cancer; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1035576446243398,"gpt":0.4507032766043178,"spread":0.3471456319799779,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004576333,0.0003061931,0.000974673,0.0002367458,0.00005128216,0.000009920001,0.0002007575,0.0002250228,0.0001512007],"category_scores_gemma":[0.00009462432,0.0002667698,0.0002971616,0.000263714,0.000397978,0.0002099337,0.00006935806,0.0002962928,0.00001481158],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001327918,"about_ca_system_score_gemma":0.001538257,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004082735,"about_ca_topic_score_gemma":0.0001013358,"domain_scores_codex":[0.9976171,0.0001141818,0.0008272671,0.0005368493,0.0003815709,0.0005230667],"domain_scores_gemma":[0.9980429,0.0005983115,0.0003036507,0.0003837305,0.0004929525,0.0001785025],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.129747,0.0009944886,0.0004032942,0.0007694232,0.0007908566,0.0003053223,0.001821514,0.000253758,0.05634258,0.0007592387,0.003389776,0.8044228],"study_design_scores_gemma":[0.08314753,0.04076596,0.01728279,0.003075813,0.0003199512,0.001933855,0.001236614,0.001140657,0.2543641,0.008231947,0.5872734,0.001227382],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9699497,0.006044035,0.0001542605,0.01660919,0.001012695,0.001108974,0.003995148,0.00009666292,0.001029295],"genre_scores_gemma":[0.9940402,0.001569897,0.001185322,0.001266143,0.0009260236,0.0002654065,0.0002316016,0.00006865562,0.000446755],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8031954,"threshold_uncertainty_score":0.9999784,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2887054120","doi":"10.1080/15384101.2018.1502567","title":"Targeting the cell cycle in breast cancer: towards the next phase","year":2018,"lang":"en","type":"review","venue":"Cell Cycle","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Campbell Family Institute for Breast Cancer Research","keywords":"Cell cycle; Biology; Cancer; Breast cancer; Cancer research; Cancer cell; Cell growth; Bioinformatics; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.04549567917826845,"gpt":0.3511356198814667,"spread":0.3056399407031983,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005314622,0.0006039083,0.001356853,0.0001091554,0.0002445797,0.00006673859,0.0007369223,0.0002523807,0.0009596762],"category_scores_gemma":[0.00002337334,0.0003185121,0.000450327,0.0006068804,0.0003567518,0.00012877,0.0002061086,0.0009977552,0.0002980816],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004933094,"about_ca_system_score_gemma":0.0007215854,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000590821,"about_ca_topic_score_gemma":0.00002891492,"domain_scores_codex":[0.9972908,0.0002385601,0.0007128424,0.0006386038,0.0004095438,0.0007096363],"domain_scores_gemma":[0.9980075,0.0001950226,0.0004968338,0.001038924,0.0001081033,0.0001536239],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007733277,0.0002334552,0.000006809446,0.005090166,0.00007238646,0.00003327311,0.0006136101,0.00002875035,0.00006195686,0.000004636166,0.001709914,0.9920677],"study_design_scores_gemma":[0.001499187,0.00006237187,0.00001289926,0.004392952,0.0005356413,0.0001062959,0.000353496,0.0001336942,0.0001023715,0.00006312539,0.9923708,0.0003670926],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003848553,0.9921027,0.00004492289,0.0009123238,0.0006521621,0.001481583,0.0001547831,0.0000832985,0.004183414],"genre_scores_gemma":[0.002127019,0.9930062,0.0001414095,0.0006408623,0.00212843,0.000440859,0.0000654848,0.0001730932,0.00127666],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9917006,"threshold_uncertainty_score":0.9999536,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2154488022","doi":"10.1158/1078-0432.ccr-10-1869","title":"Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study","year":2011,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital du Saint-Sacrement","funders":"National Cancer Institute","keywords":"Gefitinib; Tamoxifen; Medicine; Internal medicine; Breast cancer; Placebo; Oncology; Metastatic breast cancer; Cancer; Epidermal growth factor receptor; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1388367152218822,"gpt":0.4788527990782955,"spread":0.3400160838564134,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004436493,0.0003454167,0.001581318,0.0004962795,0.0001490347,0.00002382245,0.0002840496,0.0001100532,0.000930579],"category_scores_gemma":[0.0005759289,0.000212437,0.00009166516,0.001548803,0.001072644,0.0003245221,0.0001493975,0.001398504,0.00001267418],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008296515,"about_ca_system_score_gemma":0.001219423,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005320702,"about_ca_topic_score_gemma":0.004722929,"domain_scores_codex":[0.9939038,0.001915366,0.001109016,0.0008761091,0.001385785,0.0008099162],"domain_scores_gemma":[0.9961843,0.001534297,0.0003012376,0.0005018764,0.001127031,0.000351248],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7565652,0.01397453,0.1697223,0.0000515158,0.0004840563,0.0001235735,0.004356192,0.000007261037,0.00001354871,0.00002339111,0.00006166049,0.05461674],"study_design_scores_gemma":[0.6195373,0.01954836,0.3580247,0.0007307403,0.0001569466,0.000006041534,0.001442654,0.00006467284,0.00005096229,0.00011004,0.0000680138,0.0002595125],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896954,0.0004983054,0.00006760738,0.0009855692,0.00008682843,0.008258254,0.0001610056,0.00004258957,0.0002044579],"genre_scores_gemma":[0.9938689,0.0003865495,0.0007393058,0.0001903079,0.0000983465,0.004195464,0.0000460652,0.00008356496,0.0003914992],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1883024,"threshold_uncertainty_score":0.9999827,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2313479654","doi":"10.1093/annonc/mdw139","title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Fulvestrant; Palbociclib; Medicine; Placebo; Internal medicine; Quality of life (healthcare); Breast cancer; Metastatic breast cancer; Oncology; Cancer; Confidence interval; Anastrozole; Gynecology; Estrogen receptor; Tamoxifen","retraction":null,"screen_n_in":null,"score":{"opus":0.08696416881545778,"gpt":0.3862310724140349,"spread":0.2992669035985772,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005438331,0.0003088017,0.001633305,0.00009506706,0.00003920202,0.000003793346,0.000172534,0.0001282318,0.0002263098],"category_scores_gemma":[0.0005261194,0.0001541071,0.0001949736,0.0003404096,0.0007033798,0.000146117,0.00004213138,0.0001968355,0.000002968855],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000195173,"about_ca_system_score_gemma":0.0009843336,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01134751,"about_ca_topic_score_gemma":0.002561502,"domain_scores_codex":[0.9966678,0.0007783722,0.001290485,0.0004207595,0.000433803,0.0004087759],"domain_scores_gemma":[0.9953089,0.002084833,0.00139862,0.0004727977,0.0005680029,0.0001668958],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4161136,0.002052668,0.2629928,0.00007141413,0.004197678,0.00008746792,0.006823941,0.00002689679,0.01528627,0.00007891057,0.0003376536,0.2919307],"study_design_scores_gemma":[0.1053178,0.00754232,0.8771815,0.000412241,0.0002500655,0.00002196959,0.001464498,0.000002365508,0.006820292,0.0003891143,0.0003597108,0.0002382021],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819459,0.001010183,0.00009091135,0.01418386,0.00009787821,0.001678897,0.0008087656,0.00003044201,0.0001531797],"genre_scores_gemma":[0.9971638,0.0007366595,0.0006337848,0.001024795,0.00007119131,0.0002516036,0.00003343875,0.00003473054,0.00005000457],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6141886,"threshold_uncertainty_score":0.995236,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2719623628","doi":"10.1634/theoncologist.2017-0072","title":"Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"Cancer Research UK; AstraZeneca; American Society of Clinical Oncology; Pfizer","keywords":"Palbociclib; Fulvestrant; Medicine; Goserelin; Anastrozole; Internal medicine; Oncology; Breast cancer; Adverse effect; Neutropenia; Placebo; Letrozole; Gynecology; Cancer; Metastatic breast cancer; Chemotherapy; Tamoxifen","retraction":null,"screen_n_in":null,"score":{"opus":0.02206593019534308,"gpt":0.3371386426214998,"spread":0.3150727124261567,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002995182,0.0003219509,0.0004976324,0.00005313869,0.0003886244,0.00006266612,0.0002871,0.0000608854,0.00002835875],"category_scores_gemma":[0.00003776151,0.0001531973,0.00001638395,0.0001068331,0.000988199,0.000180777,0.00007025772,0.0003768025,0.000002523155],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003448621,"about_ca_system_score_gemma":0.0002447782,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00018743,"about_ca_topic_score_gemma":0.0007256797,"domain_scores_codex":[0.9982732,0.00006838008,0.0002704791,0.0004886982,0.0003599646,0.0005393102],"domain_scores_gemma":[0.9984123,0.0001112568,0.0003822666,0.0008507885,0.00009553602,0.0001478903],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2487009,0.0007418265,0.0403353,0.00007491041,0.0001767207,0.0003994837,0.002023934,0.00009134987,0.007364981,0.0001081168,0.0000224937,0.69996],"study_design_scores_gemma":[0.03727097,0.01476186,0.9398801,0.0009472894,0.00003616068,0.0002935355,0.0007724527,0.00002247919,0.002495643,0.0001502883,0.003081044,0.0002881226],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9813605,0.0003978201,0.000005208969,0.01516129,0.00006601561,0.001648497,0.00005621009,0.00008880354,0.001215668],"genre_scores_gemma":[0.9970024,0.0005228762,0.0007079193,0.0004145923,0.0001241536,0.0007225432,0.000007627903,0.00004899911,0.0004488642],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8995448,"threshold_uncertainty_score":0.6247206,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3035496509","doi":"10.1158/1078-0432.ccr-20-0224","title":"<i>ESR1</i> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Institute for Health and Care Research; Cancer Research UK; AstraZeneca","keywords":"Fulvestrant; Exemestane; Oncology; Breast cancer; Medicine; Internal medicine; Hormone receptor; Estrogen receptor; Oestrogen receptor; Cancer; Aromatase","retraction":null,"screen_n_in":null,"score":{"opus":0.2207194958004969,"gpt":0.5247294331244319,"spread":0.304009937323935,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002543433,0.0002469872,0.001592029,0.0002313059,0.0001459854,0.00002702932,0.0002068719,0.0001462723,0.0001766702],"category_scores_gemma":[0.001660861,0.0001754534,0.0003008241,0.001858082,0.001042447,0.0001226445,0.0001427642,0.001023426,0.000001373476],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002573758,"about_ca_system_score_gemma":0.0006120249,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009857628,"about_ca_topic_score_gemma":0.000816708,"domain_scores_codex":[0.9954967,0.001343754,0.001097868,0.0007282161,0.0008576406,0.0004757965],"domain_scores_gemma":[0.9937202,0.004710219,0.0003152068,0.0003927729,0.0004458621,0.0004157047],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5414643,0.002169677,0.07550047,0.0003115091,0.006865925,0.00008856709,0.003148191,0.001191832,0.05446593,0.0007898055,0.0004198866,0.3135839],"study_design_scores_gemma":[0.151529,0.00911658,0.8264967,0.0007861182,0.002459199,0.000005588662,0.001549572,0.002459398,0.003470085,0.0002697023,0.001331125,0.0005269199],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9779891,0.003020388,0.00004176344,0.01621478,0.0002118139,0.001432048,0.0009639049,0.00002455979,0.0001015966],"genre_scores_gemma":[0.992815,0.005997189,0.00009464566,0.0004856441,0.0002264031,0.0002436337,0.00004773264,0.00003396296,0.00005582886],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7509962,"threshold_uncertainty_score":0.7154784,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2791840917","doi":"10.1093/annonc/mdy012","title":"Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Letrozole; Medicine; Palbociclib; Quality of life (healthcare); Breast cancer; Internal medicine; Metastatic breast cancer; Oncology; Placebo; Gynecology; Cancer; Tamoxifen","retraction":null,"screen_n_in":null,"score":{"opus":0.2086520558681569,"gpt":0.4783877348419532,"spread":0.2697356789737964,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001119762,0.0001760254,0.001218425,0.00008383189,0.00004937645,0.000001522035,0.0001625138,0.0001986275,0.0001618197],"category_scores_gemma":[0.002305159,0.0001140978,0.0003155841,0.0002843757,0.0006398166,0.00004664585,0.00004947964,0.0002395674,0.000006941485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001218832,"about_ca_system_score_gemma":0.001382405,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009364652,"about_ca_topic_score_gemma":0.000268803,"domain_scores_codex":[0.9965065,0.0005750908,0.001938096,0.0002905288,0.0003764136,0.0003134224],"domain_scores_gemma":[0.9945548,0.001250277,0.002685562,0.0007202491,0.0006350526,0.000154015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7630915,0.002288513,0.01029639,0.00005512231,0.002348278,0.00001464199,0.009777103,0.00008923378,0.01034491,0.0001717562,0.00960608,0.1919165],"study_design_scores_gemma":[0.1866594,0.09808912,0.690421,0.0003447289,0.0001183147,0.00001568503,0.001047835,0.0000406637,0.01225196,0.001989745,0.008766989,0.00025452],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889522,0.0007303304,0.00001721538,0.007543191,0.0003710347,0.0007197621,0.0003733668,0.00002406064,0.001268876],"genre_scores_gemma":[0.9978349,0.00008854597,0.0001735742,0.001473501,0.0002732753,0.00001233127,0.00008898679,0.00001986069,0.0000350877],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6801246,"threshold_uncertainty_score":0.9972321,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2077037832","doi":"10.1016/j.clbc.2013.10.016","title":"Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer","year":2013,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"Merck","keywords":"Medicine; Capecitabine; Oncology; Breast cancer; Randomized controlled trial; Internal medicine; Cancer; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.02014164253463134,"gpt":0.3471441605379508,"spread":0.3270025180033195,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007102184,0.0006379546,0.002266287,0.0001544913,0.0001569206,0.0000258363,0.000470214,0.0003042762,0.00222313],"category_scores_gemma":[0.0004231244,0.0003841194,0.0006500065,0.0006852327,0.001229274,0.0004661818,0.0002714677,0.0009508395,0.00002218536],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005928298,"about_ca_system_score_gemma":0.0007476647,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001163199,"about_ca_topic_score_gemma":0.0003615925,"domain_scores_codex":[0.9945728,0.0004593972,0.002074622,0.0009873607,0.001094853,0.0008109654],"domain_scores_gemma":[0.9956139,0.0008202872,0.001082149,0.001119168,0.0008877214,0.0004767854],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.766441,0.004497262,0.02904811,0.00006999733,0.0004461997,0.00000613363,0.0001158161,0.00008606171,0.0002419787,0.00002208495,0.0001234299,0.198902],"study_design_scores_gemma":[0.8377685,0.001861849,0.1575958,0.0008721678,0.0004719827,0.000009660178,0.0001045659,0.00007627709,0.0002527585,0.00006646404,0.0004982018,0.0004218085],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9829748,0.0006048027,0.00002273122,0.006465147,0.003384894,0.005560443,0.0007192072,0.00007835169,0.0001896338],"genre_scores_gemma":[0.9945513,0.0003302591,0.0002199111,0.0008281284,0.001444783,0.002057454,0.00003394544,0.0001203025,0.0004139306],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1984802,"threshold_uncertainty_score":0.9998611,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2805363969","doi":"10.1200/jco.2018.36.18_suppl.lba1006","title":"Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) <i>v</i> FULV in patients (pts) with estrogen receptor (ER)-positive, <i>PIK3CA</i> -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Ottawa Hospital","funders":"","keywords":"Fulvestrant; Medicine; Metastatic breast cancer; Internal medicine; Clinical endpoint; Hazard ratio; Adverse effect; Oncology; Population; Randomized controlled trial; Cancer; Breast cancer; Placebo; Progression-free survival; Estrogen receptor; Confidence interval; Overall survival; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.03734654690843785,"gpt":0.4099493458190268,"spread":0.3726027989105889,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001811644,0.0005527406,0.004731328,0.0004982658,0.00008938895,0.00001737799,0.0004916049,0.0002925983,0.0008659762],"category_scores_gemma":[0.0004703025,0.0003550783,0.0006037431,0.001528882,0.000854985,0.0004845019,0.0001081161,0.001257702,0.000007486028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007446855,"about_ca_system_score_gemma":0.003199355,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004930017,"about_ca_topic_score_gemma":0.001853759,"domain_scores_codex":[0.991483,0.001023262,0.004817358,0.0007548712,0.001280561,0.000640911],"domain_scores_gemma":[0.9905584,0.001722978,0.004367364,0.0006211866,0.002000502,0.0007295684],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.346207,0.05063626,0.2144692,0.00006935655,0.01416714,0.001100162,0.001514699,0.0006242607,0.003577727,0.00000330594,0.000222473,0.3674084],"study_design_scores_gemma":[0.3555254,0.2011365,0.4123382,0.001253039,0.01801751,0.000310423,0.003674246,0.0002196936,0.002053117,0.00007178188,0.004525074,0.000875049],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936599,0.0006191469,0.00204773,0.00105913,0.0006323796,0.001254804,0.000618031,0.00002069636,0.00008823501],"genre_scores_gemma":[0.9846236,0.0004528423,0.01188537,0.002072985,0.0007352486,0.00004950769,0.00006752134,0.00007147663,0.00004142978],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3665334,"threshold_uncertainty_score":0.9998901,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4379645953","doi":"10.1200/jco.2023.41.17_suppl.lba500","title":"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Letrozole; Breast cancer; Clinical endpoint; Tolerability; Internal medicine; Anastrozole; Population; Oncology; Interim analysis; Goserelin; Cancer; Surgery; Gynecology; Randomized controlled trial; Tamoxifen; Adverse effect","retraction":null,"screen_n_in":null,"score":{"opus":0.07422391342854126,"gpt":0.4508825997255233,"spread":0.3766586862969821,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001126023,0.0002321772,0.001593645,0.0001069639,0.00005825485,0.00001291635,0.0001775223,0.0001646253,0.00007170611],"category_scores_gemma":[0.0004131212,0.0001162903,0.0002123557,0.0002736806,0.0003360513,0.0001691755,0.00004757347,0.0006973994,0.000009418523],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003838703,"about_ca_system_score_gemma":0.001370262,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001046716,"about_ca_topic_score_gemma":0.0002622869,"domain_scores_codex":[0.9965333,0.0004311677,0.001911818,0.0003247281,0.0004766503,0.0003223052],"domain_scores_gemma":[0.9946154,0.003075915,0.001441677,0.0003032858,0.0002831328,0.0002806364],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.4239222,0.002224968,0.07380299,0.00000252065,0.0004818736,0.0004218074,0.0003928413,0.000006899409,0.00002571492,0.000002992803,0.0002054637,0.4985097],"study_design_scores_gemma":[0.3718432,0.02681236,0.5740592,0.0001145192,0.0001292832,0.00006158945,0.00009906081,0.000004558206,0.00001876098,0.0001142472,0.02666365,0.00007953325],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9796555,0.001346893,0.000003914434,0.01700131,0.0007082021,0.0008796942,0.0002164745,0.00002105465,0.0001669518],"genre_scores_gemma":[0.9886286,0.006737418,0.0002820543,0.002404349,0.001552628,0.00004322954,0.00004425314,0.00003613333,0.0002712983],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5002562,"threshold_uncertainty_score":0.474218,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2808476554","doi":"10.3747/co.25.3752","title":"Overcoming Endocrine Resistance in Hormone Receptor–Positive Breast Cancer","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false},"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Breast cancer; Hormone receptor; Endocrine system; Hormone; Cancer; Bioinformatics; Resistance (ecology); Receptor; Cancer research; Internal medicine; Oncology; Computational biology; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.1127109070422267,"gpt":0.4602473066929266,"spread":0.3475363996506999,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002432871,0.0006747395,0.0030972,0.0004063163,0.00007110754,0.00001182062,0.0003040171,0.000361887,0.0004859098],"category_scores_gemma":[0.00007634879,0.0005738668,0.0003991751,0.0006646112,0.0003848198,0.0001159717,0.0001774159,0.001239981,0.0001727403],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004445275,"about_ca_system_score_gemma":0.001461224,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003972318,"about_ca_topic_score_gemma":0.0002817741,"domain_scores_codex":[0.9967419,0.0003130449,0.0009645012,0.0009168097,0.0002960644,0.0007676971],"domain_scores_gemma":[0.9979922,0.0002987914,0.000668665,0.0005646863,0.0002525112,0.0002231648],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000605547,0.0003643452,0.00009546083,0.006952606,0.0002214367,0.00008800289,0.0001947449,6.735113e-8,0.000005331362,0.0001161898,0.004595387,0.9867609],"study_design_scores_gemma":[0.002104332,0.0001924933,0.0004473952,0.03394066,0.0006206649,0.000386757,0.00002396342,6.390087e-7,0.000002110442,0.00007047087,0.9617599,0.0004506324],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004715362,0.9936611,0.00004740154,0.000473357,0.002309249,0.001417944,0.0006170364,0.00008002044,0.001346722],"genre_scores_gemma":[0.00001896006,0.9945809,0.0007193022,0.0000917707,0.002555679,0.0008669752,0.0002741957,0.0001226958,0.0007694914],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9863102,"threshold_uncertainty_score":0.9996713,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2925092419","doi":"10.1056/nejmoa1811714","title":"Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre; Cancer Care Ontario","funders":"National Cancer Institute","keywords":"Anastrozole; Fulvestrant; Medicine; Oncology; Aromatase inhibitor; Metastatic breast cancer; Internal medicine; Aromatase; Breast cancer; Cancer; Tamoxifen; Estrogen receptor; Progression-free survival; Overall survival","retraction":null,"screen_n_in":null,"score":{"opus":0.01613558606668913,"gpt":0.2899758635197193,"spread":0.2738402774530302,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004838842,0.0002057322,0.0008411653,0.0002470005,0.00001468398,0.00000574361,0.0001157248,0.00003224788,0.001040114],"category_scores_gemma":[0.00002751608,0.000117731,0.00005480228,0.0002376438,0.00009742473,0.0001835199,0.00001066761,0.0004769971,0.000004907137],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002205867,"about_ca_system_score_gemma":0.0006379827,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006785398,"about_ca_topic_score_gemma":0.0003275482,"domain_scores_codex":[0.9983039,0.000066052,0.0005050509,0.0001610622,0.0006684496,0.0002954114],"domain_scores_gemma":[0.9988732,0.0001155677,0.0003176162,0.000183691,0.0001929308,0.0003169339],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05306078,0.0003603701,0.4590597,0.0005278108,0.001334147,0.003289557,0.0057102,0.0109321,0.02710343,0.0004768454,0.000871982,0.4372731],"study_design_scores_gemma":[0.3511469,0.005106139,0.5920163,0.004897148,0.0005790354,0.01700284,0.00169212,0.0002958654,0.0003855464,0.0005443792,0.02598504,0.0003487192],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9786615,0.002269406,0.001169747,0.01654592,0.0005755243,0.0002423203,0.000009002059,0.00001136584,0.0005151956],"genre_scores_gemma":[0.9951838,0.0002801339,0.001305639,0.0007308581,0.001880021,0.000002043616,0.000003669989,0.00003085058,0.0005829679],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4369243,"threshold_uncertainty_score":0.999873,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2149472508","doi":"10.1007/s10637-007-9090-3","title":"A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Pharmacokinetics; Cmax; Medicine; Tolerability; Bioavailability; Nausea; Adverse effect; Pharmacology; Pharmacodynamics; Maximum tolerated dose; Cyclin-dependent kinase; Dysgeusia; Toxicity; Refractory (planetary science); Oral administration; Internal medicine; Cancer; Cell cycle","retraction":null,"screen_n_in":null,"score":{"opus":0.02381757120153434,"gpt":0.3125895757310258,"spread":0.2887720045294915,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002651473,0.0002332769,0.0005150862,0.000320833,0.00004410428,0.00001171183,0.00006114042,0.00004369171,0.00001940673],"category_scores_gemma":[0.0001732399,0.0001914081,0.00002964168,0.0002742355,0.0003147099,0.0002669471,0.00005670627,0.0001594493,8.600413e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001169715,"about_ca_system_score_gemma":0.0003916759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004618927,"about_ca_topic_score_gemma":0.0002173437,"domain_scores_codex":[0.9979231,0.0000593974,0.0007305066,0.0003297668,0.0007341933,0.0002230624],"domain_scores_gemma":[0.9986618,0.0001585688,0.0004689942,0.0001868535,0.0002221084,0.0003017165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04251535,0.03188136,0.5890997,0.0009556744,0.0007533231,0.0003367946,0.05403939,0.0001630507,0.1017863,0.0002255556,0.00005582016,0.1781877],"study_design_scores_gemma":[0.07007293,0.03068002,0.8636373,0.001475278,0.0002843017,0.00007953712,0.01015793,0.00005233263,0.02121229,0.001830064,0.00009743703,0.0004205737],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984275,0.0001860421,0.00002765666,0.0002217094,0.00003795378,0.001001688,0.00003499659,0.00001656032,0.0000459465],"genre_scores_gemma":[0.9965206,0.000003258761,0.003044,0.000232081,0.00003837705,0.00001808957,0.00004956705,0.00002880197,0.00006521206],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2745376,"threshold_uncertainty_score":0.7805396,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2037157828","doi":"10.1016/j.clbc.2013.08.011","title":"Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor–Positive Breast Cancer in BOLERO-2","year":2013,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Sunnybrook Health Science Centre; University of Toronto","funders":"Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Exemestane; Medicine; Everolimus; Breast cancer; Oncology; Internal medicine; Hormone receptor; Aromatase; Cancer; Gynecology","retraction":null,"screen_n_in":null,"score":{"opus":0.009278835326357648,"gpt":0.2903044741973232,"spread":0.2810256388709656,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003244843,0.0006147909,0.001672004,0.0002202714,0.00006607875,0.00002466077,0.0002215523,0.0002878138,0.0008007568],"category_scores_gemma":[0.00007202429,0.000448456,0.0001104579,0.0009284216,0.001154575,0.0005257457,0.0001025532,0.0008858973,0.00001276426],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006038055,"about_ca_system_score_gemma":0.0005425698,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008351845,"about_ca_topic_score_gemma":0.002781872,"domain_scores_codex":[0.9958433,0.0002262514,0.001352464,0.001064372,0.0007022753,0.0008113628],"domain_scores_gemma":[0.9968758,0.000566213,0.0006132699,0.0005834135,0.0008674758,0.0004938205],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0516322,0.001454247,0.6972159,0.0001037463,0.000315792,0.00003263195,0.0004932471,0.0001156204,0.0002500658,0.00001113795,0.00006593342,0.2483094],"study_design_scores_gemma":[0.03665011,0.002062334,0.9573401,0.002551789,0.0001544309,0.00008428402,0.0002331361,0.00006189253,0.00009766408,0.00003296763,0.0002018912,0.0005294398],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910856,0.001120382,0.00007765364,0.004462792,0.0001391281,0.002152397,0.0007610025,0.0000572924,0.0001437866],"genre_scores_gemma":[0.9951111,0.001913373,0.001256822,0.0007944156,0.0002030845,0.0003479285,0.00005430928,0.0001241141,0.0001948523],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2601241,"threshold_uncertainty_score":0.9997967,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2783341375","doi":"10.1093/annonc/mdx797","title":"Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Medicine; Letrozole; Fulvestrant; Internal medicine; Hazard ratio; Breast cancer; Oncology; Metastatic breast cancer; Cancer; Placebo; Gynecology; Gastroenterology; Confidence interval; Estrogen receptor; Tamoxifen; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.04509901211439402,"gpt":0.4148736468886414,"spread":0.3697746347742473,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002811744,0.00008547995,0.0004377404,0.00004241518,0.00002398211,9.133414e-7,0.00008674542,0.00004125813,0.00005302839],"category_scores_gemma":[0.00002739695,0.00004552008,0.00005416133,0.0001384329,0.0009645617,0.00005048328,0.00004952913,0.00008606859,1.523974e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000009790336,"about_ca_system_score_gemma":0.0001124055,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008948827,"about_ca_topic_score_gemma":0.0003107587,"domain_scores_codex":[0.9989488,0.000150957,0.0004656621,0.0001334499,0.0001808881,0.0001202057],"domain_scores_gemma":[0.9987439,0.0001536969,0.0004379182,0.0002442329,0.0003945471,0.00002572458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002981461,0.001069586,0.8585342,0.0001186662,0.0005310004,0.000001302904,0.001248263,0.00003258888,0.0007433642,0.00206903,0.00005969626,0.1326109],"study_design_scores_gemma":[0.004143289,0.002258379,0.984426,0.0002653116,0.0001620981,0.00001052775,0.001160442,0.000008719469,0.004352129,0.001574206,0.001590432,0.00004849656],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961059,0.0005201312,0.00001074163,0.002017192,0.00004422741,0.0004574143,0.0001049619,0.000002441637,0.0007369582],"genre_scores_gemma":[0.9976093,0.0001828841,0.001487829,0.0006441201,0.00002591503,0.00002760061,0.000002546782,0.000007816274,0.0000120595],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1325624,"threshold_uncertainty_score":0.3553968,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4410927250","doi":"10.1056/nejmoa2502929","title":"First-Line Camizestrant for Emerging <i>ESR1</i> -Mutated Advanced Breast Cancer","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Agence Nationale de la Recherche; AstraZeneca","keywords":"Breast cancer; Line (geometry); Oncology; Cancer research; Cancer; Computational biology; Medicine; Biology; Internal medicine; Mathematics","retraction":null,"screen_n_in":null,"score":{"opus":0.01292950396255306,"gpt":0.3241416641217435,"spread":0.3112121601591905,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004880411,0.0002647099,0.0008890067,0.0003240056,0.00009963644,0.000006989854,0.0001646198,0.00007506627,0.0002583912],"category_scores_gemma":[0.0002493045,0.0001770041,0.0001502309,0.0004243176,0.0001329214,0.0001474288,0.00001733884,0.0003937468,9.227521e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002149288,"about_ca_system_score_gemma":0.0005351508,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001681586,"about_ca_topic_score_gemma":0.0001240956,"domain_scores_codex":[0.9981717,0.0000318564,0.000816435,0.0002167496,0.0004034899,0.0003597662],"domain_scores_gemma":[0.9980793,0.00030566,0.0004280418,0.0002143406,0.0006610773,0.0003115802],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01697596,0.0001211457,0.003564293,0.0004056391,0.0006718953,0.0001710229,0.0009442293,0.003614902,0.02082193,0.0002025416,0.003941759,0.9485647],"study_design_scores_gemma":[0.3757048,0.002860855,0.02042884,0.01098786,0.001912429,0.004949161,0.0008667334,0.00111735,0.006304455,0.005985574,0.5684262,0.0004557566],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.3621407,0.0469549,0.1844462,0.3963957,0.006815989,0.0017085,0.0001178507,0.0001570045,0.001263093],"genre_scores_gemma":[0.9792309,0.003302717,0.005071228,0.003940177,0.006019331,0.00002295713,0.0000151023,0.0000535197,0.002344066],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.9481089,"threshold_uncertainty_score":0.7218019,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2702886506","doi":"10.1200/jco.2016.34.15_suppl.507","title":"PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Palbociclib; Letrozole; Clinical endpoint; Internal medicine; Hazard ratio; Breast cancer; Cancer; Progression-free survival; Adverse effect; Oncology; Gynecology; Randomized controlled trial; Metastatic breast cancer; Confidence interval; Tamoxifen; Overall survival","retraction":null,"screen_n_in":null,"score":{"opus":0.04252982893718386,"gpt":0.4039353674576152,"spread":0.3614055385204313,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017106,0.0004495024,0.003782515,0.0002602124,0.00005036652,0.000009453734,0.0003585256,0.0003297014,0.0002259633],"category_scores_gemma":[0.0003422746,0.0002303586,0.0001649946,0.0004471624,0.001026989,0.0004676962,0.00006609793,0.001079452,0.000004118377],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001052514,"about_ca_system_score_gemma":0.003917209,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003107267,"about_ca_topic_score_gemma":0.0008748047,"domain_scores_codex":[0.9937519,0.0005156895,0.003446762,0.0005861861,0.0009906038,0.0007088649],"domain_scores_gemma":[0.9911332,0.002418898,0.004347284,0.0005613596,0.0008681803,0.0006710397],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.764905,0.005309836,0.01085168,0.00002824293,0.001162854,0.001122568,0.000470172,0.0001057313,0.008204206,0.000005974044,0.0001039013,0.2077298],"study_design_scores_gemma":[0.7184447,0.09296251,0.1756796,0.001542901,0.0004322712,0.0007056424,0.0006225737,0.000009048992,0.0005567351,0.00009431411,0.008605695,0.0003440203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987689,0.0004586286,0.0006532563,0.009098107,0.0003994381,0.0008593499,0.0003846194,0.00002807851,0.000429561],"genre_scores_gemma":[0.9878516,0.0004029858,0.008559393,0.001515122,0.001320721,0.00007192846,0.00001963478,0.00007880771,0.0001798372],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2073857,"threshold_uncertainty_score":0.939375,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1558355135","doi":"10.1002/cncr.28010","title":"Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial","year":2013,"lang":"en","type":"article","venue":"Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Cambridge Memorial Hospital","funders":"National Cancer Institute; Sanofi; Celgene; AstraZeneca; Chugai Pharmaceutical; Amgen; Pfizer; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Exemestane; Everolimus; Breast cancer; Internal medicine; Quality of life (healthcare); Placebo; Discontinuation; Oncology; Hazard ratio; Clinical endpoint; Randomized controlled trial; Aromatase inhibitor; Cancer; Gynecology; Confidence interval; Tamoxifen; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.02037856840053433,"gpt":0.3230547976171125,"spread":0.3026762292165782,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009022833,0.0005987433,0.004261708,0.000215,0.00008904003,0.00001672879,0.0002883443,0.0001633585,0.0006801174],"category_scores_gemma":[0.0002507436,0.0003277659,0.0002946204,0.0007984798,0.0007695784,0.000318853,0.00003102625,0.0004531475,0.000002945317],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001050697,"about_ca_system_score_gemma":0.002097248,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009899464,"about_ca_topic_score_gemma":0.001275515,"domain_scores_codex":[0.9948435,0.0007858044,0.001959938,0.0006032384,0.001101468,0.000706083],"domain_scores_gemma":[0.9949683,0.001005358,0.002015576,0.0007468846,0.0009558858,0.0003080243],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9749988,0.0008079759,0.002267929,0.0002862708,0.001342552,0.00000810393,0.001768348,0.002173226,0.0001153797,0.00004886543,0.00006404693,0.01611856],"study_design_scores_gemma":[0.980668,0.002517447,0.01351114,0.0008200576,0.0005086347,0.000007391543,0.0009953533,0.0004430363,0.00006903765,0.00001857325,0.00008447492,0.0003568422],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9756876,0.007118377,0.0001555654,0.001910313,0.0003294582,0.0141641,0.0003590973,0.00006433075,0.0002111512],"genre_scores_gemma":[0.9931617,0.0007479032,0.0002078361,0.0004826764,0.0001210863,0.00488855,0.00009903063,0.00008871853,0.0002025334],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01747406,"threshold_uncertainty_score":0.9999174,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2060696690","doi":"10.1016/j.lungcan.2013.11.020","title":"Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"Merck Sharp and Dohme","keywords":"Medicine; Erlotinib; Internal medicine; Neutropenia; Oncology; Lung cancer; Adverse effect; Surgery; Cancer; Epidermal growth factor receptor; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.009580312840794003,"gpt":0.2976431150917498,"spread":0.2880628022509558,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002262297,0.0004329357,0.001067783,0.000146339,0.00009520655,0.00002482737,0.0002970542,0.0001076987,0.0005708982],"category_scores_gemma":[0.0000531396,0.0002698772,0.0001641382,0.0004598594,0.0001831878,0.0002151642,0.000128974,0.0004563308,0.000004706781],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007136589,"about_ca_system_score_gemma":0.0003442752,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005714357,"about_ca_topic_score_gemma":0.001863826,"domain_scores_codex":[0.997247,0.0001898348,0.0007124066,0.0005867099,0.0007161128,0.0005478832],"domain_scores_gemma":[0.9980309,0.0002015215,0.0005078805,0.0007205385,0.0003609029,0.0001782632],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2773912,0.004462022,0.6978638,0.0005351587,0.0008956105,0.00001795597,0.007144295,0.00133556,0.001844974,0.000005092978,0.0003264945,0.008177772],"study_design_scores_gemma":[0.8903041,0.0009852032,0.09665453,0.0009962561,0.001105928,7.233725e-7,0.001571974,0.0009017686,0.006871242,0.000006985354,0.0001372718,0.0004640158],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9876316,0.001929677,0.00004281231,0.0002946352,0.001312217,0.008305837,0.00005427971,0.00004602,0.0003828831],"genre_scores_gemma":[0.9952396,0.00008477559,0.0001229571,0.0002296794,0.0002914731,0.003122915,0.000009540511,0.0000962286,0.0008027866],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6129129,"threshold_uncertainty_score":0.9999753,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4379508645","doi":"10.1177/17588359231178125","title":"Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy <i>versus</i> endocrine therapy alone in patients with HR+/HER2− early breast cancer","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Genentech; PharmaMar; Novartis Institutes for BioMedical Research; Daewoong Pharmaceutical Company; Astellas Pharma; Eisai; Seagen; Mersana Therapeutics; Mylan; Syndax Pharmaceuticals; Clovis Oncology; Astex Pharmaceuticals; Merck KGaA; Taiho Pharmaceutical; F. Hoffmann-La Roche; Amgen; Radius Health; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Exelixis; Sanofi; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Letrozole; Internal medicine; Breast cancer; Clinical endpoint; Oncology; Anastrozole; Palbociclib; Metastatic breast cancer; Goserelin; Randomization; Cancer; Adjuvant therapy; Clinical trial; Tamoxifen; Gynecology","retraction":null,"screen_n_in":null,"score":{"opus":0.0373529934834873,"gpt":0.3836976276393478,"spread":0.3463446341558605,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008249028,0.0004252307,0.001658713,0.0004234684,0.00005049731,0.000005214655,0.0003099437,0.0002044239,0.0005287065],"category_scores_gemma":[0.0001187148,0.0003113406,0.000104322,0.001059228,0.001117121,0.0003305318,0.00006786959,0.0005880766,0.000002245],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002576988,"about_ca_system_score_gemma":0.0009079584,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001680168,"about_ca_topic_score_gemma":0.0001519643,"domain_scores_codex":[0.9958051,0.0004989966,0.001236815,0.0006071044,0.001187426,0.0006645039],"domain_scores_gemma":[0.9970915,0.001466271,0.0005772582,0.0003942134,0.0002426967,0.0002280944],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.568946,0.002565065,0.002403034,0.00003627621,0.0002088671,0.00007326146,0.0005420698,0.00008733958,0.0004594721,0.0000765626,0.000006189832,0.4245959],"study_design_scores_gemma":[0.9492896,0.02887766,0.008946215,0.0002706157,0.00006929176,0.00003717082,0.0002623628,0.0002437464,0.0009863175,0.0006868613,0.01001485,0.000315296],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980725,0.01008897,0.001059784,0.002196681,0.0008011831,0.004871085,0.000113436,0.0000717459,0.00007210241],"genre_scores_gemma":[0.9679568,0.02882211,0.0007962419,0.0007241347,0.0004101239,0.0010714,0.00008391463,0.00007604025,0.0000591705],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4242806,"threshold_uncertainty_score":0.9999338,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2884436796","doi":"10.1093/jnci/djy109","title":"Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer","year":2018,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"David Geffen School of Medicine, University of California, Los Angeles; BC Cancer Agency; Robert H. Lurie Comprehensive Cancer Center; Russian Science Foundation; Peter MacCallum Cancer Centre; Feinberg School of Medicine; Pfizer","keywords":"Palbociclib; Fulvestrant; Letrozole; Medicine; Internal medicine; Adverse effect; Breast cancer; Oncology; Placebo; Neutropenia; Metastatic breast cancer; Cancer; Gynecology; Chemotherapy; Tamoxifen","retraction":null,"screen_n_in":null,"score":{"opus":0.0272881053857524,"gpt":0.3613495205114768,"spread":0.3340614151257245,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003569367,0.000209245,0.0006343923,0.0005204479,0.000112642,0.00001286062,0.0002919033,0.00005963685,0.0002193108],"category_scores_gemma":[0.00007673799,0.0001327068,0.0002936128,0.001412242,0.0003371372,0.0004707954,0.00002695926,0.0002418152,3.751086e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001025926,"about_ca_system_score_gemma":0.001055799,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001177697,"about_ca_topic_score_gemma":0.002015671,"domain_scores_codex":[0.9978353,0.00004816613,0.0007192529,0.0002128301,0.0009467016,0.0002377437],"domain_scores_gemma":[0.9959149,0.00009608547,0.0009783916,0.0001756976,0.002751295,0.00008364695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04854534,0.001152699,0.6637084,0.0001989899,0.009199739,0.00001756344,0.001143317,0.04005587,0.03134526,0.001681933,0.0002117416,0.2027391],"study_design_scores_gemma":[0.01462756,0.0004976145,0.9685189,0.0006132956,0.0008576642,0.0001265935,0.00003337826,0.0004514122,0.009840694,0.0003941755,0.003865317,0.0001734513],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866924,0.00143901,0.002683749,0.006968287,0.0009356426,0.0007090327,0.0004291667,0.00001149558,0.0001311971],"genre_scores_gemma":[0.9960771,0.0007040705,0.00107663,0.001077372,0.0007460051,0.00007810971,0.000022601,0.00002668441,0.0001914201],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3048104,"threshold_uncertainty_score":0.5411627,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2950856878","doi":"10.1634/theoncologist.2019-0019","title":"Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; University of Calgary; University of Alberta","funders":"Genentech; Pfizer","keywords":"Letrozole; Palbociclib; Medicine; Oncology; Internal medicine; Postmenopausal women; Randomized controlled trial; Breast cancer; Cancer; Gynecology; Tamoxifen; Metastatic breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.006386544342530553,"gpt":0.2729757012801935,"spread":0.2665891569376629,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009739283,0.0003407684,0.002030791,0.0001600523,0.0001025222,0.00001311234,0.0004290497,0.0001137351,0.0006128011],"category_scores_gemma":[0.00007351371,0.0001400992,0.0001880457,0.001681742,0.001085396,0.0001005537,0.00009426703,0.0004103775,0.000006666522],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007656435,"about_ca_system_score_gemma":0.0004577709,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007122763,"about_ca_topic_score_gemma":0.001425655,"domain_scores_codex":[0.9973913,0.0004888927,0.0006335208,0.0004375234,0.0005136718,0.0005350605],"domain_scores_gemma":[0.9975091,0.0006617699,0.0006786918,0.0009057162,0.0001584155,0.0000862832],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.948518,0.0003858662,0.03558128,0.00005046358,0.002402587,0.00002202407,0.001073222,0.005502708,0.001111121,0.0003483636,0.000006766729,0.004997637],"study_design_scores_gemma":[0.8193256,0.003196773,0.1693054,0.0002681282,0.002350341,0.0001465815,0.003201554,0.000378333,0.0003898745,0.0002337326,0.0008287422,0.0003749496],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897326,0.0004929054,0.00008447516,0.004695114,0.0001468969,0.003255115,0.00009032962,0.0000592807,0.00144334],"genre_scores_gemma":[0.9973052,0.000121712,0.0003246208,0.0007680294,0.00006583508,0.0006696353,0.00001438093,0.00003596873,0.00069464],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1337241,"threshold_uncertainty_score":0.6709743,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2798042703","doi":"10.1007/s10549-018-4769-z","title":"Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2","year":2018,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation","keywords":"Letrozole; Medicine; Breast cancer; Internal medicine; Quality of life (healthcare); Placebo; Oncology; Cancer; Gynecology; Tamoxifen; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.04369723222632609,"gpt":0.3575200797900653,"spread":0.3138228475637392,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004329112,0.0006944181,0.001803508,0.0003537786,0.0004336368,0.00002958878,0.0002135618,0.0001750112,0.0008382844],"category_scores_gemma":[0.00005182799,0.000469176,0.00008435336,0.001088412,0.002208779,0.000382649,0.00009764371,0.0004557323,0.00001036282],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002696792,"about_ca_system_score_gemma":0.001653642,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1057212,"about_ca_topic_score_gemma":0.004186042,"domain_scores_codex":[0.9943773,0.0006046666,0.001200618,0.001210122,0.001319654,0.00128767],"domain_scores_gemma":[0.9945971,0.000472111,0.0009358799,0.0006731019,0.002241488,0.001080327],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5038301,0.004463556,0.1622529,0.0003493576,0.008691511,0.00005555798,0.01025714,0.00002240695,0.1426743,0.000154016,0.0002801269,0.1669691],"study_design_scores_gemma":[0.03449718,0.01819902,0.9151814,0.0009948385,0.00009049653,0.00006360989,0.001525425,0.000005507058,0.02879973,0.00008643216,0.0001059339,0.0004504676],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9607669,0.003007128,0.00001128545,0.005549501,0.00003655007,0.001963292,0.02838714,0.00008716918,0.0001910606],"genre_scores_gemma":[0.9950591,0.001833866,0.0007865796,0.00009954956,0.0002683534,0.000821151,0.0005018841,0.0001200785,0.0005094138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7529285,"threshold_uncertainty_score":0.999776,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2765692744","doi":"10.1007/s10549-017-4523-y","title":"Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial","year":2017,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; University of Ottawa; Occupational Cancer Research Centre","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation","keywords":"Letrozole; Medicine; Breast cancer; Hazard ratio; Discontinuation; Internal medicine; Placebo; Metastatic breast cancer; Clinical endpoint; Population; Nausea; Oncology; Cancer; Surgery; Randomized controlled trial; Tamoxifen; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.02442456894890639,"gpt":0.337798520493771,"spread":0.3133739515448646,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006893151,0.0005120921,0.001178162,0.0003048308,0.0005719981,0.0001936476,0.000326626,0.0001153178,0.000176638],"category_scores_gemma":[0.00003834832,0.0002731179,0.0001103782,0.0004343262,0.001474596,0.0004734977,0.00008684689,0.0006011521,0.000008521683],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001436493,"about_ca_system_score_gemma":0.0006818007,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.05661977,"about_ca_topic_score_gemma":0.0217359,"domain_scores_codex":[0.9959686,0.0005324702,0.0004282403,0.0008109722,0.0012488,0.001010931],"domain_scores_gemma":[0.9977186,0.0004314923,0.0002696999,0.0007510787,0.0005240965,0.0003050252],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7885268,0.001924467,0.1204166,0.00003009596,0.0006800535,0.0001400201,0.001347714,0.00002118772,0.0000556901,0.00004768188,0.00005066161,0.08675903],"study_design_scores_gemma":[0.4577591,0.003194101,0.5373721,0.0005170451,0.00008739816,0.00005627532,0.0003793065,0.00001447667,0.0001583034,0.00007414258,0.0001765273,0.000211245],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9778152,0.001745473,0.00001173934,0.01317404,0.00005884342,0.005613049,0.001110425,0.00002578348,0.0004454682],"genre_scores_gemma":[0.9911084,0.002287779,0.0001628197,0.00011733,0.0003313895,0.005384447,0.00006526524,0.00006995089,0.0004726831],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4169555,"threshold_uncertainty_score":0.9999721,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3049702673","doi":"10.1016/j.ctrv.2020.102086","title":"Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis","year":2020,"lang":"en","type":"article","venue":"Cancer Treatment Reviews","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Palbociclib; Medicine; Fulvestrant; Tolerability; Metastatic breast cancer; Internal medicine; Oncology; Adverse effect; Neutropenia; Discontinuation; Breast cancer; Hazard ratio; Pharmacology; Cancer; Chemotherapy; Estrogen receptor; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.1381587461601385,"gpt":0.405004672436912,"spread":0.2668459262767735,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001600175,0.0007456171,0.006243234,0.0002349993,0.00004555761,0.000003444625,0.0001687646,0.00009077136,0.00170309],"category_scores_gemma":[0.00001518822,0.0004596861,0.002652629,0.001521859,0.0001110025,0.0001092866,0.00004509998,0.0001582756,0.00001299726],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001706954,"about_ca_system_score_gemma":0.0002749288,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002328117,"about_ca_topic_score_gemma":0.001847163,"domain_scores_codex":[0.995777,0.0004195295,0.002153955,0.0007610099,0.0004032224,0.000485275],"domain_scores_gemma":[0.9972579,0.0001091586,0.001498679,0.0006739383,0.0001123966,0.0003479549],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.001839936,0.00350981,0.5756865,0.0009207398,0.206137,0.00005110854,0.003476573,0.0401513,0.001612142,0.00002540413,0.00005960133,0.1665299],"study_design_scores_gemma":[0.02328795,0.004351235,0.06173586,0.001160334,0.8769237,0.00001910753,0.0007676081,0.003155827,0.01324862,0.0001040396,0.0140893,0.001156425],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.4316022,0.5591402,0.000210654,0.00234144,0.0002420428,0.005309591,0.0009912589,0.00006739979,0.00009516309],"genre_scores_gemma":[0.957544,0.03928404,0.000516298,0.0001774946,0.0001043726,0.00195728,0.0001377866,0.00005629367,0.0002224932],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.6707867,"threshold_uncertainty_score":0.9997855,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3174841530","doi":"10.1038/s41416-021-01415-9","title":"Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer","year":2021,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Breast cancer; Medicine; Oncology; Hormone receptor; Cancer; Internal medicine; Oestrogen receptor; Clinical trial; Hormone","retraction":null,"screen_n_in":null,"score":{"opus":0.01697719221813876,"gpt":0.3431304860266393,"spread":0.3261532938085006,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001188418,0.0001870507,0.00115894,0.0001585302,0.00006318581,0.00003112397,0.00008051106,0.00007683451,0.0002027566],"category_scores_gemma":[0.0007425473,0.0001463536,0.0002316945,0.0004726381,0.0002291118,0.0002357582,0.00001999666,0.0005308268,1.557687e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004439634,"about_ca_system_score_gemma":0.0006084856,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001755574,"about_ca_topic_score_gemma":0.001094065,"domain_scores_codex":[0.9975713,0.0006134402,0.0009903403,0.0002293665,0.000361873,0.000233665],"domain_scores_gemma":[0.9976595,0.001009341,0.0006608432,0.000123024,0.0004231077,0.0001241832],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1044282,0.0007422061,0.006903409,0.00006705061,0.0008556269,0.0004540421,0.002521452,0.002828301,0.04404943,0.00001644149,0.0002267684,0.836907],"study_design_scores_gemma":[0.06949982,0.0003717647,0.9198782,0.003093616,0.0001590407,0.003004876,0.001011104,0.00000943898,0.002280616,0.0001192014,0.0004269653,0.0001452865],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9453079,0.05045981,0.00001512782,0.002975773,0.0001269694,0.0005888196,0.0004109328,0.000003774524,0.0001108631],"genre_scores_gemma":[0.9345278,0.06447294,0.0003781225,0.0001900757,0.0002902948,0.00004283754,0.000005281851,0.00002398883,0.0000687297],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9129748,"threshold_uncertainty_score":0.5968125,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}